Clinical Commander

Back to dossier
ob.vte-in-pregnancy.v1PRODUCTION
ob.vte-in-pregnancy.v1

VTE in Pregnancy and Postpartum

obstetricsacutesubacuteadultpregnancy
Hard-required inputs
0 / 13
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

VTE in pregnancy and postpartum — pregnant and postpartum patients have 4-5x increased VTE risk vs non-pregnant; ~ 80% events are venous; prevalence 0.5-2.0 per 1000 pregnant women per ACOG PB 196 (PMID 29939938). VTE accounts for ~ 9.3% of US maternal deaths. Anticoagulation choice is tailored to pregnancy because warfarin is teratogenic (PregCat X in pregnancy; warfarin embryopathy 6-12 wk; fetal hemorrhage later) and DOACs lack pregnancy/lactation evidence and are contraindicated. LMWH (enoxaparin) is the backbone per ASH 2018 (Bates PMID 30482767) STRONG recommendation over UFH for acute VTE; UFH only near delivery and in eGFR < 30. Diagnosis uses pregnancy-adapted YEARS algorithm for PE (van der Pol 2019 PMID 30893534).

Inputs
1
Actions
0
Advance rule
Set
Advance when

GA / postpartum interval documented; VTE pretest probability and anticoagulation framework set

Patient inputs (21)

Prior VTE is a major risk factor; ACOG PB 196 stratifies prophylactic anticoagulation by prior VTE type (unprovoked / hormonally associated / provoked)

Inherited (FVL, prothrombin gene, antithrombin deficiency, protein C/S deficiency) or acquired (APS) thrombophilia drives prophylactic anticoagulation indication

Weight-based LMWH dosing (enoxaparin 1 mg/kg q12h therapeutic); BMI > 30 raises VTE risk and prophylaxis indication

Avoid DOAC continuation in pregnancy (CONTRAINDICATED); transition warfarin to LMWH/UFH as soon as pregnancy recognised; document current dose and last administration timing

GA + postpartum interval drive anticoagulation choice (LMWH throughout pregnancy; UFH transition near delivery; warfarin postpartum only); also drives duration of anticoagulation (3 mo total OR 6 wk postpartum, whichever longer)

Baseline for anticoagulation; rule out HIT (heparin-induced thrombocytopenia) if drop in platelets within 5-10 d of heparin exposure

eGFR < 30 mL/min/1.73 m² → UFH preferred over LMWH (renal clearance); creatinine for LMWH dose adjustment

Baseline; aPTT for UFH monitoring if used; PT/INR for warfarin transition postpartum

First-line for suspected DVT in pregnancy (no radiation, high sensitivity for proximal DVT); MRV preferred for iliofemoral DVT given pregnant uterus impedes pelvic US

Hypotension in massive PE drives thrombolysis decision; baseline for shock monitoring

Tachycardia in PE; baseline for monitoring + sPESI scoring

Hypoxemia in PE; oxygen support; severity marker

Tachypnea in PE; respiratory failure marker for intubation/ECMO consideration

Cesarean delivery doubles postpartum VTE risk; mode of delivery influences prophylactic anticoagulation decision postpartum

Major risk factors per ACOG PB 196: BMI > 30, smoking, prolonged immobility, hyperemesis with dehydration, pre-eclampsia, multifetal gestation

Pregnancy-adapted YEARS algorithm (van der Pol 2019 PMID 30893534) — modified D-dimer thresholds + clinical YEARS items allow safe PE exclusion without imaging in ~ 39% of patients

For PE workup when YEARS criteria not met or D-dimer above threshold; CTPA preferred unless CXR-clear young patient (V/Q lower radiation to maternal breast; both have minimal fetal exposure)

Baseline for V/Q decision; rules out pneumonia/pneumothorax; usually normal in PE

S1Q3T3 pattern, sinus tachycardia, RV strain pattern; usually nonspecific but obtained at presentation

Submassive PE risk stratification — elevated troponin / BNP with RV strain on echo → consider escalated therapy

RV strain pattern (McConnell sign, septal flattening, RV dilation) supports submassive/massive PE; differentiates from cardiogenic shock / AFE

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningvte_massive_pe_thrombolysis
    Massive PE with hemodynamic instability (SBP < 90, cardiac arrest, refractory shock) in pregnant or postpartum patient — alteplase 100 mg IV over 2 h (50 mg bolus if arrest); ICU + multidisciplinary; survival benefit outweighs hemorrhage risk for life-threatening indication.
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverevte_acute_first_line_lmwh
    Acute VTE (DVT or PE) in pregnant or postpartum patient — first-line therapeutic enoxaparin 1 mg/kg SC q12h (weight-based) per ASH 2018 STRONG recommendation (Bates PMID 30482767); duration 3 mo total OR 6 wk postpartum (whichever longer) per ACOG PB 196 (PMID 29939938).
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverevte_DOAC_in_pregnancy_immediate_switch
    DOAC (apixaban, rivaroxaban, dabigatran, edoxaban) use in newly diagnosed or planned pregnancy → IMMEDIATE switch to LMWH (enoxaparin 1 mg/kg SC q12h therapeutic OR prophylactic dose per indication); DOACs CONTRAINDICATED in pregnancy AND lactation per ASH 2018 (Bates PMID 30482767).
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverevte_HIT_suspicion_switch_to_argatroban
    Platelet drop > 50% from baseline within 5-10 d of heparin exposure (LMWH or UFH) → HIT suspicion; STOP heparin + send 4T score + HIT antibodies + functional assay; switch to argatroban (off-label in pregnancy but case-series support; fondaparinux alternative also off-label).
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatevte_delivery_transition_planning
    Anticoagulation transition planning at 34-36 wk — switch therapeutic enoxaparin to UFH 24 h before scheduled induction/elective cesarean (12 h for prophylactic); enables neuraxial anesthesia per ASRA + ACOG PB 196 guidance; resume 4-6 h post-vaginal / 6-12 h post-cesarean per hemostasis.
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatevte_prior_history_subsequent_pregnancy_prophylaxis
    Prior VTE history in subsequent pregnancy → prophylactic LMWH throughout pregnancy + 6 wk postpartum per ACOG PB 196 + ASH 2018 (PMIDs 29939938 + 30482767); dose stratified by VTE history type (unprovoked / hormonally associated / provoked).
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSoptionalDrives screening
Loading…

Recommended regimen

VTE in pregnancy and postpartum — LMWH backbone + UFH transition near delivery + warfarin postpartum only + alteplase for massive PE + IVC filter for absolute anticoagulation contraindication + DOACs explicitly CONTRAINDICATED (ACOG PB 196 PMID 29939938 + ASH 2018 Bates PMID 30482767 + van der Pol YEARS NEJM 2019 PMID 30893534)
axis: vte_in_pregnancy_anticoagulation_and_thrombolysis
Selected axis "VTE in pregnancy and postpartum — LMWH backbone + UFH transition near delivery + warfarin postpartum only + alteplase for massive PE + IVC filter for absolute anticoagulation contraindication + DOACs explicitly CONTRAINDICATED (ACOG PB 196 PMID 29939938 + ASH 2018 Bates PMID 30482767 + van der Pol YEARS NEJM 2019 PMID 30893534)" by default fallback (first axis)
  • enoxaparin
    first line
    low_molecular_weight_heparin
    Therapeutic: 1 mg/kg SC q12h (weight-based). Prophylactic: 40 mg SC daily (or 30 mg SC q12h if BMI > 40) • SC • q12h therapeutic; daily prophylactic
    triggers: acute_vte_in_pregnancy_or_postpartum, prophylaxis_for_high_risk_pregnancy
    PregCat: former B — extensive pregnancy experience; LMWH does not cross placenta (large molecular weight ~ 4-6 kDa). | Lactation: compatible per LactMed — large molecular weight prevents milk transfer; routinely used postpartum. | First-line acute VTE treatment per ASH 2018 STRONG recommendation (Bates PMID 30482767) over UFH because of more predictable PK, lower HIT risk, and outpatient feasibility; weight-based dosing q12h preferred (twice-daily preferred to once-daily in pregnancy per conditional ASH recommendation due to expanded plasma volume + glomerular hyperfiltration); anti-Xa monitoring NOT routine.
    rxcui 67108
  • heparin
    second line
    unfractionated_heparin
    Therapeutic: 80 units/kg IV bolus + 18 units/kg/h infusion; titrate aPTT 1.5-2.5x control. Prophylactic SC: 5000 units SC q8-12h • IV/SC • continuous (therapeutic IV) or q8-12h (prophylactic SC)
    triggers: eGFR_lt_30_mL_per_min, near_delivery_within_24h, rapid_anticoagulation_reversal_needed
    PregCat: former C — long pregnancy experience; UFH does not cross placenta. | Lactation: compatible per LactMed — does not transfer in significant amounts; routine postpartum use. | Reserved per ASH 2018 (Bates PMID 30482767) for renal impairment (eGFR < 30 favors UFH given LMWH renal clearance) or near-delivery period when shorter half-life + IV reversibility (protamine) is advantageous; transition from LMWH to UFH 24 h before scheduled induction/elective cesarean for therapeutic dose, 12 h before for prophylactic — enables neuraxial anesthesia per ASRA + ACOG PB 196 guidance.
    rxcui 5224
  • warfarin
    first line
    vitamin_k_antagonist
    5 mg PO daily POSTPARTUM ONLY; titrate to INR 2-3 (target depends on indication and bridging plan) • PO • daily
    triggers: postpartum_continued_anticoagulation_no_pregnancy_planned
    PregCat: former X in pregnancy — warfarin embryopathy (nasal hypoplasia, stippled epiphyses) at 6-12 wk; fetal CNS abnormalities + fetal hemorrhage later in pregnancy; STRICTLY CONTRAINDICATED throughout pregnancy. | Lactation: compatible POSTPARTUM per LactMed — does not transfer to breast milk in significant amounts; safe during breastfeeding. | Standard postpartum anticoagulation option when continued therapy needed beyond 6 wk postpartum; bridge with LMWH/UFH until INR therapeutic for 24-48 h then stop heparin; AVOID re-initiation if next pregnancy planned (switch back to LMWH preconception or at first positive pregnancy test).
    rxcui 11289
  • alteplase
    rescue
    tissue_plasminogen_activator_fibrinolytic
    100 mg IV over 2 h (standard PE regimen); 50 mg IV bolus if cardiac arrest • IV • single infusion
    triggers: massive_pe_with_hemodynamic_instability_or_cardiac_arrest_in_pregnancy
    PregCat: former C — large molecule unlikely to cross placenta in significant amounts but limited pregnancy data. | Lactation: limited-data per LactMed — short half-life (~ 5 min); resume breastfeeding 24-48 h post-infusion reasonable. | Reserved for LIFE-THREATENING massive PE (SBP < 90 sustained, RV failure, cardiac arrest) where survival benefit outweighs hemorrhage risk; ASH 2018 (Bates PMID 30482767) discusses thrombolysis as reasonable for life-threatening PE in pregnancy; coordinate with critical care + hematology + obstetrics + neurology for intracranial hemorrhage risk discussion; catheter-directed thrombolysis is selective alternative.
    rxcui 8410
  • IVC filter retrievable
    rescue
    mechanical_anticoagulation_alternative
    triggers: absolute_contraindication_to_anticoagulation_with_acute_VTE
    PregCat: N/A — device. | Lactation: N/A — device. | ONLY for absolute anticoagulation contraindication (active major hemorrhage, recent intracranial bleed, severe thrombocytopenia); retrievable filter preferred + remove as soon as anticoagulation feasible; framework per ACOG PB 196 (PMID 29939938) + ASH 2018 (PMID 30482767).
  • apixaban
    contraindication substitute
    direct_oral_anticoagulant_factor_Xa_inhibitor
    triggers: NEVER_use_in_pregnancy_or_lactation_documentation_only
    PregCat: former B label but CONTRAINDICATED in pregnancy per ASH 2018 (Bates PMID 30482767) — limited pregnancy data, no formal recommendation. | Lactation: CONTRAINDICATED per ASH 2018 — small molecule likely crosses into breast milk; insufficient data on infant exposure. | Documented to flag the safety rule; transition to LMWH if patient becomes pregnant while on apixaban — switch as soon as pregnancy recognised; do NOT use postpartum in breastfeeding patients.
    rxcui 1364430
  • rivaroxaban
    contraindication substitute
    direct_oral_anticoagulant_factor_Xa_inhibitor
    triggers: NEVER_use_in_pregnancy_or_lactation_documentation_only
    PregCat: former C — CONTRAINDICATED in pregnancy per ASH 2018 (Bates PMID 30482767) — placental transfer demonstrated in animal studies + insufficient human data. | Lactation: CONTRAINDICATED per ASH 2018 — small molecule crosses into milk in animal studies + insufficient human data. | Documented to flag the safety rule; transition to LMWH if patient becomes pregnant while on rivaroxaban — switch as soon as pregnancy recognised; do NOT use postpartum in breastfeeding patients.
    rxcui 1114195

outpatient playbook — drug actions (2)

  1. 1. enoxaparin therapeutic or prophylactic per indication
    rxcui 67108
    1 mg/kg SC q12h therapeutic; 40 mg SC daily prophylactic • SC • q12h or daily
    trigger: Chronic VTE management or high-risk prophylaxis
    ASH 2018 + ACOG PB 196
  2. 2. warfarin transition postpartum if continued anticoag needed
    rxcui 11289
    5 mg PO daily titrated INR 2-3 • PO • daily
    trigger: > 6 wk postpartum continued anticoagulation, not breastfeeding plan-dependent
    LactMed-compatible postpartum option

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Unilateral leg swelling + pain + erythema in pregnant or postpartum patient — DVT until proven otherwise; compression US first-line (ACOG PB 196 PMID 29939938); Pleuritic chest pain ± dyspnea ± hemoptysis in pregnant or postpartum patient — PE until proven otherwise; pregnancy-adapted YEARS algorithm (van der Pol 2019 PMID 30893534); Unexplained sinus tachycardia (HR > 100) or hypoxemia (SpO2 < 95% on room air) in pregnant or postpartum patient — PE workup mandatory.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**VTE in Pregnancy and Postpartum** (ob.vte-in-pregnancy.v1).
Phenotype framing: DVT differential: cellulitis (warmth, redness, no Homan sign), superficial venous thrombosis (palpable cord), ruptured Baker cyst (popliteal), lymphedema (pitting, gradual), trauma/hematoma, post-thrombotic syndrome (if prior VTE). PE differential: pneumonia (fever, productive cough, focal infiltrate), peripartum cardiomyopathy (cardiomegaly, BNP markedly elevated, LV dysfunction), amniotic fluid embolism (sudden intrapartum/immediate postpartum collapse + DIC), acute coronary syndrome (chest pain, ECG, troponin), pneumothorax (decreased breath sounds, CXR), anxiety/hyperventilation (clinical exclusion), costochondritis (reproducible CW tenderness), aortic dissection (rare in young pregnant patient).
Scope: VTE in pregnancy and postpartum — pregnant and postpartum patients have 4-5x increased VTE risk vs non-pregnant; ~ 80% events are venous; prevalence 0.5-2.0 per 1000 pregnant women per ACOG PB 196 (PMID 29939938). VTE accounts for ~ 9.3% of US maternal deaths. Anticoagulation choice is tailored to pregnancy because warfarin is teratogenic (PregCat X in pregnancy; warfarin embryopathy 6-12 wk; fetal hemorrhage later) and DOACs lack pregnancy/lactation evidence and are contraindicated. LMWH (enoxaparin) is the backbone per ASH 2018 (Bates PMID 30482767) STRONG recommendation over UFH for acute VTE; UFH only near delivery and in eGFR < 30. Diagnosis uses pregnancy-adapted YEARS algorithm for PE (van der Pol 2019 PMID 30893534).

No severity triggers fired against current inputs.

Plan

Regimen axis: **VTE in pregnancy and postpartum — LMWH backbone + UFH transition near delivery + warfarin postpartum only + alteplase for massive PE + IVC filter for absolute anticoagulation contraindication + DOACs explicitly CONTRAINDICATED (ACOG PB 196 PMID 29939938 + ASH 2018 Bates PMID 30482767 + van der Pol YEARS NEJM 2019 PMID 30893534)**.
1. enoxaparin Therapeutic: 1 mg/kg SC q12h (weight-based). Prophylactic: 40 mg SC daily (or 30 mg SC q12h if BMI > 40) SC q12h therapeutic; daily prophylactic (low_molecular_weight_heparin, first line) — PregCat: former B — extensive pregnancy experience; LMWH does not cross placenta (large molecular weight ~ 4-6 kDa). | Lactation: compatible per LactMed — large molecular weight prevents milk transfer; routinely used postpartum. | First-line acute VTE treatment per ASH 2018 STRONG recommendation (Bates PMID 30482767) over UFH because of more predictable PK, lower HIT risk, and outpatient feasibility; weight-based dosing q12h preferred (twice-daily preferred to once-daily in pregnancy per conditional ASH recommendation due to expanded plasma volume + glomerular hyperfiltration); anti-Xa monitoring NOT routine.
2. heparin Therapeutic: 80 units/kg IV bolus + 18 units/kg/h infusion; titrate aPTT 1.5-2.5x control. Prophylactic SC: 5000 units SC q8-12h IV/SC continuous (therapeutic IV) or q8-12h (prophylactic SC) (unfractionated_heparin, second line) — PregCat: former C — long pregnancy experience; UFH does not cross placenta. | Lactation: compatible per LactMed — does not transfer in significant amounts; routine postpartum use. | Reserved per ASH 2018 (Bates PMID 30482767) for renal impairment (eGFR < 30 favors UFH given LMWH renal clearance) or near-delivery period when shorter half-life + IV reversibility (protamine) is advantageous; transition from LMWH to UFH 24 h before scheduled induction/elective cesarean for therapeutic dose, 12 h before for prophylactic — enables neuraxial anesthesia per ASRA + ACOG PB 196 guidance.
3. warfarin 5 mg PO daily POSTPARTUM ONLY; titrate to INR 2-3 (target depends on indication and bridging plan) PO daily (vitamin_k_antagonist, first line) — PregCat: former X in pregnancy — warfarin embryopathy (nasal hypoplasia, stippled epiphyses) at 6-12 wk; fetal CNS abnormalities + fetal hemorrhage later in pregnancy; STRICTLY CONTRAINDICATED throughout pregnancy. | Lactation: compatible POSTPARTUM per LactMed — does not transfer to breast milk in significant amounts; safe during breastfeeding. | Standard postpartum anticoagulation option when continued therapy needed beyond 6 wk postpartum; bridge with LMWH/UFH until INR therapeutic for 24-48 h then stop heparin; AVOID re-initiation if next pregnancy planned (switch back to LMWH preconception or at first positive pregnancy test).
4. alteplase 100 mg IV over 2 h (standard PE regimen); 50 mg IV bolus if cardiac arrest IV single infusion (tissue_plasminogen_activator_fibrinolytic, rescue) — PregCat: former C — large molecule unlikely to cross placenta in significant amounts but limited pregnancy data. | Lactation: limited-data per LactMed — short half-life (~ 5 min); resume breastfeeding 24-48 h post-infusion reasonable. | Reserved for LIFE-THREATENING massive PE (SBP < 90 sustained, RV failure, cardiac arrest) where survival benefit outweighs hemorrhage risk; ASH 2018 (Bates PMID 30482767) discusses thrombolysis as reasonable for life-threatening PE in pregnancy; coordinate with critical care + hematology + obstetrics + neurology for intracranial hemorrhage risk discussion; catheter-directed thrombolysis is selective alternative.
5. IVC filter retrievable (mechanical_anticoagulation_alternative, rescue) — PregCat: N/A — device. | Lactation: N/A — device. | ONLY for absolute anticoagulation contraindication (active major hemorrhage, recent intracranial bleed, severe thrombocytopenia); retrievable filter preferred + remove as soon as anticoagulation feasible; framework per ACOG PB 196 (PMID 29939938) + ASH 2018 (PMID 30482767).
6. apixaban (direct_oral_anticoagulant_factor_Xa_inhibitor, contraindication substitute) — PregCat: former B label but CONTRAINDICATED in pregnancy per ASH 2018 (Bates PMID 30482767) — limited pregnancy data, no formal recommendation. | Lactation: CONTRAINDICATED per ASH 2018 — small molecule likely crosses into breast milk; insufficient data on infant exposure. | Documented to flag the safety rule; transition to LMWH if patient becomes pregnant while on apixaban — switch as soon as pregnancy recognised; do NOT use postpartum in breastfeeding patients.
7. rivaroxaban (direct_oral_anticoagulant_factor_Xa_inhibitor, contraindication substitute) — PregCat: former C — CONTRAINDICATED in pregnancy per ASH 2018 (Bates PMID 30482767) — placental transfer demonstrated in animal studies + insufficient human data. | Lactation: CONTRAINDICATED per ASH 2018 — small molecule crosses into milk in animal studies + insufficient human data. | Documented to flag the safety rule; transition to LMWH if patient becomes pregnant while on rivaroxaban — switch as soon as pregnancy recognised; do NOT use postpartum in breastfeeding patients.

Setting playbook (outpatient) — Long-term anticoagulation management — LMWH throughout pregnancy + 6 wk postpartum; transition planning around delivery; subsequent-pregnancy counseling
8. enoxaparin therapeutic or prophylactic per indication 1 mg/kg SC q12h therapeutic; 40 mg SC daily prophylactic SC q12h or daily — Chronic VTE management or high-risk prophylaxis (ASH 2018 + ACOG PB 196)
9. warfarin transition postpartum if continued anticoag needed 5 mg PO daily titrated INR 2-3 PO daily — > 6 wk postpartum continued anticoagulation, not breastfeeding plan-dependent (LactMed-compatible postpartum option)

Non-pharmacologic actions:
- Educate on transition plan at 34-36 wk
- Counsel against DOACs if next pregnancy planned
- Subsequent-pregnancy planning with MFM if applicable
- Contraception counseling avoiding combined OC

AVOID / contraindication checks:
- DOACs apixaban rivaroxaban dabigatran edoxaban CONTRAINDICATED in pregnancy AND lactation no pregnancy or lactation evidence (ASH 2018 Bates PMID 30482767)
- Warfarin CONTRAINDICATED in pregnancy embryopathy 6 to 12 wk fetal hemorrhage and CNS abnormalities throughout (ACOG PB 196 PMID 29939938)
- Warfarin compatible POSTPARTUM LactMed no milk transfer in significant amounts
- Transition LMWH to UFH 24h before scheduled delivery for therapeutic 12h prophylactic to enable neuraxial anesthesia (ASRA + ACOG PB 196)
- Resume anticoagulation 4 to 6h post vaginal or 6 to 12h post cesarean per hemostasis
- UFH preferred over LMWH if eGFR lt 30 mL per min because LMWH renal clearance (ASH 2018 Bates PMID 30482767)
- LMWH anti Xa monitoring NOT routine reserve for extremes of weight or renal impairment or recurrent VTE on therapy (ASH 2018 conditional against)
- HIT screen platelet count at day 5 to 10 of heparin therapy switch to argatroban if confirmed
- Thrombolysis only for life threatening massive PE survival benefit outweighs hemorrhage risk (ASH 2018)
- Anticoagulation duration 3 mo TOTAL OR 6 wk postpartum whichever is longer (ACOG PB 196 + ASH 2018)
- Thrombophilia workup AFTER anticoagulation completed acute thrombus and heparin confound results
- Postpartum AVOID combined OC given VTE history progestin only or non hormonal preferred

Monitoring

Regimen monitoring:
- Baseline CBC + creatinine + coag
- Platelet count day 5-10 of heparin therapy (HIT screen)
- Monthly CBC + creatinine while on LMWH
- Anti-Xa NOT routine; check at extremes of weight, renal impairment, recurrent VTE on therapy (target 0.6-1.0 IU/mL therapeutic q12h enoxaparin)
- aPTT q6h during UFH titration; target 1.5-2.5x control
- INR daily on warfarin until therapeutic 24-48 h then weekly to monthly
- Transition planning at 34-36 wk: LMWH → UFH 24 h pre-delivery (12 h for prophylactic)
- Resume anticoagulation 4-6 h post-vaginal / 6-12 h post-cesarean per hemostasis

Setting (outpatient) monitoring:
- Monthly CBC + creatinine
- Adherence assessment
- Bleeding/bruising screening

Follow-up plan: Continue anticoagulation 3 mo total OR 6 wk postpartum (whichever is longer) per ACOG PB 196 (PMID 29939938) + ASH 2018 (Bates PMID 30482767). Postpartum transition: warfarin acceptable (LactMed compatible — no milk transfer) OR continue LMWH/fondaparinux throughout breastfeeding; AVOID DOACs during breastfeeding per ASH 2018. Thrombophilia workup AFTER anticoagulation completed (acute thrombus + heparin confound results). Subsequent-pregnancy counseling: prophylactic LMWH throughout pregnancy + 6 wk postpartum if VTE in prior pregnancy or known thrombophilia (ACOG PB 196 risk-stratified). Contraception counseling: AVOID combined OCs (estrogen) given VTE history; progestin-only methods or non-hormonal preferred. Lifestyle: weight optimization, smoking cessation, mobility.
- Close-out criterion: Anticoagulation duration completed; thrombophilia workup if indicated; subsequent-pregnancy plan + contraception counseling delivered

Monitoring phase: CBC + creatinine baseline + monthly (LMWH adjustment for renal/weight changes); anti-Xa NOT routine; check if extremes of weight (< 50 kg, > 100 kg), renal impairment (CrCl < 30), recurrent VTE on therapy — target 0.6-1.0 IU/mL on therapeutic enoxaparin q12h. Platelet count d 5-10 of heparin therapy to screen HIT. Clinical reassessment q1-2 wk first month then monthly. Transition planning at 34-36 wk: switch therapeutic enoxaparin → UFH 24 h before induction/elective cesarean; prophylactic LMWH 12 h before. Resume 4-6 h post vaginal delivery / 6-12 h post cesarean.

Disposition

Current setting: outpatient — Long-term anticoagulation management — LMWH throughout pregnancy + 6 wk postpartum; transition planning around delivery; subsequent-pregnancy counseling

Disposition criteria:
- Anticoagulation duration completed (3 mo + 6 wk postpartum) → stop with thrombophilia workup if indicated
- Continued indication → maintain LMWH or transition to warfarin postpartum

Escalation triggers (move to higher acuity):
- New VTE on therapy → escalate to inpatient + evaluate adherence + dose escalation
- Bleeding complication → urgent evaluation
- Pregnancy on DOAC → urgent switch to LMWH

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Massive PE with hemodynamic instability (SBP < 90, cardiac arrest, refractory shock) in pregnant or postpartum patient — alteplase 100 mg IV over 2 h (50 mg bolus if arrest); ICU + multidisciplinary; survival benefit outweighs hemorrhage risk for life-threatening indication.
- [SEVERE] Acute VTE (DVT or PE) in pregnant or postpartum patient — first-line therapeutic enoxaparin 1 mg/kg SC q12h (weight-based) per ASH 2018 STRONG recommendation (Bates PMID 30482767); duration 3 mo total OR 6 wk postpartum (whichever longer) per ACOG PB 196 (PMID 29939938).
- [SEVERE] DOAC (apixaban, rivaroxaban, dabigatran, edoxaban) use in newly diagnosed or planned pregnancy → IMMEDIATE switch to LMWH (enoxaparin 1 mg/kg SC q12h therapeutic OR prophylactic dose per indication); DOACs CONTRAINDICATED in pregnancy AND lactation per ASH 2018 (Bates PMID 30482767).

Citations

- ACOG Practice Bulletin 196 (2018) Thromboembolism in Pregnancy + American Society of Hematology 2018 guidelines for VTE in pregnancy (Bates et al, Blood Adv) + Pregnancy-Adapted YEARS NEJM 2019 (van der Pol) for diagnostic algorithm [PMID:29939938](https://pubmed.ncbi.nlm.nih.gov/29939938/)
- Cited evidence (PMID 30482767) [PMID:30482767](https://pubmed.ncbi.nlm.nih.gov/30482767/)
- Cited evidence (PMID 30893534) [PMID:30893534](https://pubmed.ncbi.nlm.nih.gov/30893534/)

Last reconciled with current guidelines: 2026-05-26.
References
  • ACOG Practice Bulletin 196 (2018) Thromboembolism in Pregnancy + American Society of Hematology 2018 guidelines for VTE in pregnancy (Bates et al, Blood Adv) + Pregnancy-Adapted YEARS NEJM 2019 (van der Pol) for diagnostic algorithm — PMID:29939938
  • Cited evidence (PMID 30482767) — PMID:30482767
  • Cited evidence (PMID 30893534) — PMID:30893534